AbCellera announced positive top-line Phase 2 clinical trial results for ABCL635, an investigational antibody designed to treat vasomotor symptoms associated with menopause [1, 2].
The results represent a potential shift in menopause care by offering a non-hormonal alternative for women suffering from moderate-to-severe hot flashes [2, 5].
The multicenter study enrolled 92 postmenopausal women [2]. At the start of the trial, participants experienced a mean baseline frequency of approximately 10 moderate or severe hot flashes per day [2]. By week four, the trial achieved its primary efficacy endpoints, showing significant reductions in both the frequency and severity of these symptoms [3].
ABCL635 functions as a neurokinin-3 receptor antagonist antibody [2, 5]. In addition to the reduction of vasomotor symptoms, the company said the treatment improved sleep and maintained a favorable tolerability profile [2, 3].
Market reaction to the announcement on Monday was positive, though reports on the exact magnitude of the stock increase varied. Yahoo Finance reported a 34% rise in AbCellera's stock price [3], while MSN reported a 22% jump [4].
The company, headquartered in Vancouver, British Columbia, held a conference call to discuss the results at 4:30 a.m. PT / 7:30 a.m. ET [1].
“The trial achieved its primary efficacy endpoints, showing significant reductions in both the frequency and severity of these symptoms.”
The success of ABCL635 in Phase 2 trials suggests a viable pathway for a non-hormonal treatment of menopause. Because many women cannot or choose not to use hormone replacement therapy due to health risks or personal preference, a neurokinin-3 receptor antagonist could address a significant gap in the women's health market.
